Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study
Overview
- Phase
- Phase 4
- Intervention
- Duloxetine
- Conditions
- Major Depression
- Sponsor
- Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
- Enrollment
- 20
- Locations
- 2
- Primary Endpoint
- Cognitive function measured by CANTAB
- Last Updated
- 13 years ago
Overview
Brief Summary
Major depression is accompanied by cognitive changes as well as alterations in multiple physical functions. The inflammatory system is altered generally toward a pro-inflammatory state. Antidepressants are associated with a decrease in this proinflammatory state. This study aims to generate pilot data concerning a possible link between cognition, inflammation and response to treatment. The cognitive function of subjects with major depression will be tested before and after treatment with duloxetine. Inflammatory markers will be measured at both time points.
Investigators
Smadar Valerie Tourjman
MDCM, FRCPc, MSc
Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
Eligibility Criteria
Inclusion Criteria
- •Age 20-50 Primary diagnosis of major depression Ability to give informed consent
Exclusion Criteria
- •Neurologic disorders affecting cognition
- •Unstable or untreated medical disorders
- •Medical disorders associated with pain
- •Recent pregnancy or delivery
- •Psychiatric disorders other than MD which are the primary focus of treatment
- •Treatment with antidepressants in the past 4 weeks
Arms & Interventions
Duloxetine treatment
Subjects with major depression will be entered into the trial and treated with open label duloxetine
Intervention: Duloxetine
Outcomes
Primary Outcomes
Cognitive function measured by CANTAB
Time Frame: 12 weeks
Correlation between cytokines and cognitive function
Secondary Outcomes
- pain inhibition(12 weeks)
- Allostatic load(12 weeks)